Real‐world effectiveness and drug survival of guselkumab over a period of 3 years in moderate‐to‐severe plaque psoriasis, including difficult‐to‐treat areas-Reference-Cited by-同舟云学术

Real‐world effectiveness and drug survival of guselkumab over a period of 3 years in moderate‐to‐severe plaque psoriasis, including difficult‐to‐treat areas

Published:2024-07-25 Issue: Volume: Page:
ISSN:0011-9059
Container-title:International Journal of Dermatology
language:en
Short-container-title:Int J Dermatology

Author:

Rompoti Natalia¹^ORCID,Vergou Theognosia¹,Stefanaki Irene¹,Vavouli Charitomeni¹,Koumprentziotis Ioannis‐Alexios¹,Panagakis Pantelis²,Papoutsaki Marina¹,Politou Maria¹,Befon Angeliki²,Kousta Fiori²,Lazou Eleni²,Zaimi Maria¹,Chasapi Vasiliki²,Stratigos Alexander¹,Nicolaidou Electra¹

Affiliation:

1. 1st Department of Dermatology‐Venereology Medical School, National and Kapodistrian University of Athens, “A. Sygros” Hospital for Skin and Venereal Diseases Athens Greece

2. State Department of Dermatology‐Venereology “A. Sygros” Hospital for Skin and Venereal Diseases Athens Greece

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijd.17400

Reference5 articles.

1. Five‐year maintenance of clinical response and health‐related quality of life improvements in patients with moderate‐to‐severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2*

2. Real‐life experience of guselkumab in patients with psoriasis

3. Effectiveness, safety and quality‐of‐life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non‐interventional, prospective, German multicentre PERSIST study

4. Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Editor's highlights — October, 2024;International Journal of Dermatology;2024-09-02